Company news

CervoMed Inc. news in 2025

CervoMed Inc.'s news releases, calls and decks from 2025, newest first.

View company

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

December 4, 2025

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

December 2, 2025

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 24, 2025

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 10, 2025

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

November 4, 2025

CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

October 28, 2025

CervoMed to Present at the Emerging Growth Conference

October 19, 2025

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

October 8, 2025

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

October 7, 2025

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

October 2, 2025

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

September 17, 2025

CervoMed to Participate in Upcoming Investor Conferences

September 3, 2025

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 11, 2025

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

July 28, 2025

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

July 24, 2025

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

July 8, 2025

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

June 10, 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 12, 2025

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 7, 2025

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

April 2, 2025

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

March 25, 2025

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

March 17, 2025

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

March 10, 2025

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

January 30, 2025

CervoMed to Present at the 8th International Lewy Body Dementia Conference

January 28, 2025

Decks in 2025